A model for differentiating drug-induced liver injury from COVID-19-associated aminotransferase elevation in hospitalized patients
Background. Aminotransferase elevation in hospitalized patients with COVID-19 requires differentiation between drug-induced liver injury (DILI) and infection-associated abnormalities. Objective: To develop and internally validate a model differentiating DILI from COVID-19-associated aminotransferase elevation. Material and methods. Hospital records from November 1, 2021 to March 31, 2022 were reviewed retrospectively. Of 302 patients with COVID-19, 81 were included in the model development cohort: 64 with COVID-19-associated aminotransferase elevation and 17 with DILI meeting the clinical guidelines criteria. A binary logistic model included two predictors: the log₂-transformed peak-to-baseline alanine aminotransferase (ALT) ratio and age. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) with a bootstrap 95% confidence interval (CI; 1000 iterations) and five-fold cross-validation. Results. Each doubling of the peak-to-baseline ALT ratio was associated with higher odds of DILI: OR 9.59 (95% CI: 3.22–28.57; p <0.001); OR for age was 0.93 per year (95% CI: 0.86–1.00; p = 0.059). The AUC was 0.966 (95% CI: 0.903–0.999) and 0.942 in cross-validation; the Brier score was 0.053. At a probability threshold of 0.231, sensitivity was 94.1% and specificity 93.8%. An additional five-component point score achieved 94.1% sensitivity and 95.3% specificity at ≥5 points. Estimates are limited by the small number of DILI cases, the single-center retrospective design, and the use of related laboratory features for both phenotype definition and model development. Conclusion. ALT dynamics relative to baseline differentiated the selected phenotypes. External validation is required. The model does not predict liver injury before its onset.A.V. Kryukov
Keywords
drug-induced liver injury
COVID-19
alanine aminotransferase
differential diagnosis
logistic regression
ROC-curve
References
- Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–64.
PMID: 33692570. PMCID: PMC7945972. https://doi.org/10.1038/s41575-021-00426-4
- Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: A retrospective observational cohort study of 1,827 patients in a major U.S. hospital network. Hepatology. 2020;72(4):1169–76.
PMID: 32725890. PMCID: PMC9258788. https://doi.org/10.1002/hep.31487
- Shafran N, Issachar A, Shochat T, Shafran IH, Bursztyn M, Shlomai A. Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities. JHEP Rep. 2021;3(3):100258.
PMID: 33644724. PMCID: PMC7902222. https://doi.org/10.1016/j.jhepr.2021.100258
- Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036–65.
PMID: 35899384. PMCID: PMC9936988. https://doi.org/10.1002/hep.32689
- Драпкина О.М., Маев И.В., Ахмедов В.А., Вологжанина Л.Г., Долгушина А.И., Игумнова О.А. с соавт. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2024;(12):5–48. [Drapkina OM, Maev IV, Akhmedov VA, Vologzhanina LG, Dolgushina AI, Igumnova OA, et al. Drug-induced liver injury (DILI) in adults. Eksperimental'naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2024;(12):5–48 (In Russ.)].
EDN: WNKKBH. https://doi.org/10.31146/1682-8658-ecg-232-12-5-48
- European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61.
PMID: 30926241. https://doi.org/10.1016/j.jhep.2019.02.014
- Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18–31.
PMID: 35014066. PMCID: PMC9233102. https://doi.org/10.1002/hep.32327
About the Authors
Alexander V. Kryukov, MD, PhD (Medicine), head of the Department of clinical pharmacology, O.M. Filatov City Clinical Hospital No. 15; associate professor of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.E-mail: alex.kryukov90@yandex.ru
ORCID: https://orcid.org/0000-0001-7903-2977. Scopus ID: 57194714971. eLibrary SPIN: 1568-4967



